論文

査読有り 国際誌
2017年4月

Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor.

Cancer science
  • Yuki Shikata
  • Tetsuro Yoshimaru
  • Masato Komatsu
  • Hiroto Katoh
  • Reiko Sato
  • Shuhei Kanagaki
  • Yasumasa Okazaki
  • Shinya Toyokuni
  • Etsu Tashiro
  • Shumpei Ishikawa
  • Toyomasa Katagiri
  • Masaya Imoto
  • 全て表示

108
4
開始ページ
785
終了ページ
794
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/cas.13175
出版者・発行元
Cancer Science

© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. Xanthohumol (XN), a simple prenylated chalcone, can be isolated from hops and has the potential to be a cancer chemopreventive agent against several human tumor cell lines. We previously identified valosin-containing protein (VCP) as a target of XN; VCP can also play crucial roles in cancer progression and prognosis. Therefore, we investigated the molecular mechanisms governing the contribution of VCP to the antitumor activity of XN. Several human tumor cell lines were treated with XN to investigate which human tumor cell lines are sensitive to XN. Several cell lines exhibited high sensitivity to XN both in vitro and in vivo. shRNA screening and bioinformatics analysis identified that the inhibition of the adenylate cyclase (AC) pathway synergistically facilitated apoptosis induced by VCP inhibition. These results suggest that there is crosstalk between the AC pathway and VCP function, and targeting both VCP and the AC pathway is a potential chemotherapeutic strategy for a subset of tumor cells.

リンク情報
DOI
https://doi.org/10.1111/cas.13175
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28122154
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406609
URL
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85018595278&origin=inward
ID情報
  • DOI : 10.1111/cas.13175
  • ISSN : 1347-9032
  • PubMed ID : 28122154
  • PubMed Central 記事ID : PMC5406609

エクスポート
BibTeX RIS